BIIB Biogen Inc.
Price Chart
Executive Summary
Biogen and UCB presented Phase 3 PHOENYCS GO data at EULAR 2026 for dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE), showing patients achieved sustained disease control with lower glucocorticoid doses through Week 48 versus placebo. The data support DZP's potential to reduce steroid exposure and flare rates, but DZP remains investigational with no regulatory approval.
Actionable Insight
Monitor for regulatory submission updates and potential Phase 3 data from the ongoing PHOENYCS program (NCT06617325). DZP's steroid-sparing profile could differentiate it in the SLE market if approved, but near-term stock impact is limited given no approval or revenue guidance.
Key Facts
- Phase 3 PHOENYCS GO data presented at EULAR 2026: DZP plus standard of care showed sustained disease control at lower glucocorticoid doses through Week 48 vs placebo.
- Post hoc analysis: patients with baseline glucocorticoid dose >7.5 mg/day prednisone equivalent on DZP were more likely to achieve disease control while tapering to ≤7.5 mg/day.
- DZP demonstrated a generally favorable safety profile; serious treatment-emergent adverse events were less frequent in the DZP arm vs placebo.
- DZP is an investigational biologic (CD40L inhibitor) in Phase 3 development for SLE under a UCB/Biogen collaboration; not approved by any health authority.
- Phase 3 PHOENYCS GO study was recently published in The Lancet (May 29, 2026).
Financial Impact
No financial figures provided; DZP is pre-commercial with no revenue or cost data disclosed.
Risk Factors
- DZP is not approved by any regulatory authority; clinical development may fail or be delayed.
- Competition from approved SLE therapies (e.g., belimumab, anifrolumab) could limit commercial potential.
- Safety profile requires further characterization; treatment-emergent adverse events were more common with DZP vs placebo.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306500 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
4d ago
|
ANALYST-UPGRADE
| $194.60 awaiting T+1 | awaiting T+1 | — | $200.05 (+2.80%) |
|
Jun 4, 2026
9d ago
|
Press Release
| $195.82 $195.30 | ▼ −0.27% | ▲ +2.33% | $200.05 (+2.16%) |
|
Jun 1, 2026
12d ago
|
Press Release
| $192.22 $188.66 | ▼ −1.85% | ▼ −2.00% | $200.05 (+4.08%) |
|
May 31, 2026
12d ago
|
ANALYST-UPGRADE
| $156.63 $154.99 | ▼ −1.05% | ▼ −1.18% | $200.05 (+27.72%) |
|
May 22, 2026
21d ago
|
ANALYST-UPGRADE
| $190.12 $187.84 | ▼ −1.20% | ▼ −0.81% | $200.05 (+5.22%) |
|
May 21, 2026
22d ago
|
Press Release
| $193.85 $193.07 | ▲ +0.40% | ▲ +0.99% | $200.05 (−3.20%) |
|
May 20, 2026
23d ago
|
ANALYST-UPGRADE
| $183.33 $185.18 | ▲ +1.01% | ▲ +1.66% | $200.05 (+9.12%) |
|
May 14, 2026
29d ago
|
ANALYST-UPGRADE
| $178.76 $180.47 | ▲ +0.96% | ▲ +0.18% | $200.05 (+11.91%) |
|
May 14, 2026
29d ago
|
Press Release
| $191.26 $192.32 | ▲ +0.55% | ▲ +1.78% | $200.05 (+4.60%) |
|
May 14, 2026
29d ago
|
8-K
| $191.26 $192.32 | ▲ +0.55% | ▲ +1.78% | $200.05 (+4.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access